Meeting
2018 ASCO Annual Meeting
A phase I/II study of the combination of temozolomide (TM) and pazopanib (PZ) in advanced pancreatic neuroendocrine tumors (PNETs) (NCT01465659).
Authors
Manali A. Bhave
Northwestern University, Chicago, IL
Manali A. Bhave , Sheetal Mehta Kircher , Aparna Kalyan , Jordan Berlin , Mary Frances Mulcahy , Steven J. Cohen , Crystal S. Denlinger , E. Gabriela Chiorean , Vaibhav Sahai , Mark Zalupski , Alfred Rademaker , Al Bowen Benson III, Halla Nimeiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Clinical Trial Registration Number
NCT01465659
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4096)
DOI
10.1200/JCO.2018.36.15_suppl.4096
Abstract #
4096
Poster Bd #
285
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
A phase I multicenter study of the combination of temozolomide and pazopanib in advanced pancreatic neuroendocrine tumors (PNET).
First Author: Aparna Kalyan
Poster
2018 ASCO Annual Meeting
Phase 1 multicenter trial to assess the maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.
First Author: Kieuhoa Tran Vo
Poster
2023 ASCO Annual Meeting
A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors.
First Author: Pei Shu
Poster
2020 ASCO Virtual Scientific Program
Phase I trial of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.
First Author: Kieuhoa T. Vo